Shmona Simpson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Shmona Simpson has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Ajoy Chakrabarti
The Bill and Melinda Gates Foundation, 500 5th Ave N, Seattle, WA, 98109, USA
2 shared publications- Ajoy C. Chakrabarti
Bill & Melinda Gates Foundation, Seattle, USA
1 shared publication Casey Selwyn
Bill & Melinda Gates Foundation, Seattle, USA
1 shared publicationDavid Robinson
The Bill and Melinda Gates Foundation, 500 5th Ave N, Seattle, WA, 98109, USA
1 shared publication- Georgina A. V. Murphy
Nuffield Department of Medicine, Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, UK
1 shared publication Keith Chirgwin
The Bill and Melinda Gates Foundation, 500 5th Ave N, Seattle, WA, 98109, USA
1 shared publication
Latest Publications
- Open Access
- 22 April 2021
- Published by Springer Nature in npj Vaccines
- Vol. 6 (1) , 1-8
Recommendations for acceleration of vaccine development and emergency use filings for COVID-19 leveraging lessons from the novel oral polio vaccine
A new oral polio vaccine, nOPV2, has become the first vaccine to pursue a WHO Emergency Use Listing. Many lessons were learned as part of the accelerated development plan and submission, which have been categorized under the following sections: regulatory, clinical development, chemistry manufacturing and controls, and post-deployment monitoring. Efforts were made to adapt findings from these studies to COVID-19 vaccine candidates. Specific concepts for accelerating COVID-19 vaccine development across multiple functional domains were also included. The goals of this effort were twofold: (1) to help familiarize vaccine developers with the EUL process; and (2) to provide general guidance for faster development and preparations for launch during the COVID-19 pandemic.
- 22 April 2021
- Published by Springer Nature in npj Vaccines
- Vol. 6 (1) , 1-8
Open AccessRecommendations for acceleration of vaccine development and emergency use filings for COVID-19 leveraging lessons from the novel oral polio vaccine
A new oral polio vaccine, nOPV2, has become the first vaccine to pursue a WHO Emergency Use Listing. Many lessons were learned as part of the accelerated development plan and submission, which have been categorized under the following sections: regulatory, clinical development, chemistry manufacturing and controls, and post-deployment monitoring. Efforts were made to adapt findings from these studies to COVID-19 vaccine candidates. Specific concepts for accelerating COVID-19 vaccine development across multiple functional domains were also included. The goals of this effort were twofold: (1) to help familiarize vaccine developers with the EUL process; and (2) to provide general guidance for faster development and preparations for launch during the COVID-19 pandemic.
- Open Access
- 23 October 2020
- Published by Springer Nature in npj Vaccines
- Vol. 5 (1) , 1-9
Navigating facilitated regulatory pathways during a disease X pandemic
In 2018, the Bill and Melinda Gates Foundation convened over thirty subject matter experts in clinical development, manufacturing, and regulatory assessment to determine how the development and approval of medical countermeasures could be accelerated in the event of Disease X. Disease X is the result of a presently unknown pathogen with epidemic or pandemic potential. A key opportunity to accelerate the scientific assessment and regulatory approval of medical countermeasures exists within efficient navigation of facilitated regulatory pathways. It was identified that not all stakeholders will be able to skillfully navigate the facilitated pathways offered by the various regulatory agencies during a public health emergency. To democratize this knowledge, we have written an overview of the facilitated approaches which have been developed and refined by Stringent Regulatory Authorities and the World Health Organization for the primary assessment of medical products. We discuss the conditions necessary for use of these approaches, scenarios in which certain pathways may be applicable, and the pros and cons of these approaches. We also address opportunities available to developers in, or developers who wish to access, low-income countries that may have nascent regulatory frameworks.
- 23 October 2020
- Published by Springer Nature in npj Vaccines
- Vol. 5 (1) , 1-9
Open AccessNavigating facilitated regulatory pathways during a disease X pandemic
In 2018, the Bill and Melinda Gates Foundation convened over thirty subject matter experts in clinical development, manufacturing, and regulatory assessment to determine how the development and approval of medical countermeasures could be accelerated in the event of Disease X. Disease X is the result of a presently unknown pathogen with epidemic or pandemic potential. A key opportunity to accelerate the scientific assessment and regulatory approval of medical countermeasures exists within efficient navigation of facilitated regulatory pathways. It was identified that not all stakeholders will be able to skillfully navigate the facilitated pathways offered by the various regulatory agencies during a public health emergency. To democratize this knowledge, we have written an overview of the facilitated approaches which have been developed and refined by Stringent Regulatory Authorities and the World Health Organization for the primary assessment of medical products. We discuss the conditions necessary for use of these approaches, scenarios in which certain pathways may be applicable, and the pros and cons of these approaches. We also address opportunities available to developers in, or developers who wish to access, low-income countries that may have nascent regulatory frameworks.
- 1 May 2020
- Published by Elsevier in The Lancet Infectious Diseases
- Vol. 20 (5) , e108-e115
Disease X: accelerating the development of medical countermeasures for the next pandemic
- 1 May 2020
- Published by Elsevier in The Lancet Infectious Diseases
- Vol. 20 (5) , e108-e115
Disease X: accelerating the development of medical countermeasures for the next pandemic
- Open Access
- 1 August 2019
- Published by Elsevier in The Lancet Haematology
- Vol. 6 (8) , e393-e394
Sickle cell disease: a new era
- 1 August 2019
- Published by Elsevier in The Lancet Haematology
- Vol. 6 (8) , e393-e394
Open AccessSickle cell disease: a new era